Market revenue in 2023 | USD 16,273.0 million |
Market revenue in 2030 | USD 25,488.3 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Liquid delivery device |
Fastest growing segment | Liquid Delivery Device |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 43.94% in 2023. Horizon Databook has segmented the Europe intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
Europe is one of the most developed regions in the world. Increasing public and private investment in R&D are some of the significant factors that contribute to the growth of this region. Rising demand for healthcare devices and growing prevalence of chronic diseases such as chronic sinusitis are some major drivers anticipated to boost regional growth.
Growing healthcare expenditure in this region is expected to boost technological advancement in the healthcare industry, which is one of the factors responsible for driving the intranasal drug and vaccine delivery market.
Apart from these abovementioned factors, favorable reimbursement policies, increased government investments in long-term healthcare, and rise in healthcare research infrastructural framework are also likely to propel the usage rate of intranasal drug & vaccine delivery devices.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe intranasal drug and vaccine delivery market , including forecasts for subscribers. This continent databook contains high-level insights into Europe intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account